Phase 3RecruitingPriority 2 · High priorityNCT06122389
SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma
Plain-language summary
This Phase 3 trial is comparing different first-line treatment approaches for people newly diagnosed with T-cell lymphoma. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.
Who can join (key eligibility)
- Age 18 Years to 70 Years years
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
SHR2554; Chidamide analog tablets (DRUG): SHR2554 + Chidamide analog tablets | SHR2554 analog tablets; Chidamide (DRUG): SHR2554 analog tablets + Chidamide
- Drugs / treatments
- SHR2554; Chidamide analog tablets, SHR2554 analog tablets; Chidamide
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details